Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TMI-1 (WAY-171318) 是一种有效的抑制剂,用于抑制去整合素金属酶17 (ADAM17) 和其他基质金属蛋白酶MMPs。TMI-1 能够有效地抑制LPS 诱导的人原代单核细胞和人全血中TNF-α的分泌。TMI-1 在三阴性 (TN) 和过度表达ERBB2的乳腺肿瘤细胞系中选择性地诱导Caspase 依赖的细胞凋亡。
产品描述 | TMI-1 (WAY-171318), a novel orally active inhibitor of ADAM17 (TACE) and MMP, induces tumor apoptosis in a breast cancer. |
靶点活性 | ADAM8:21 nM(ki), MMP9:12 nM, MMP2:4.7 nM, TNF-α secretion (Raw cells):40 nM, MMP14:26 nM, ADAMTS-4:100 nM, MMP7:26 nM, ADAM12:1.8 nM(ki), ADAM17/TACE:0.079 nM(ki), TNF-α secretion (THP-1 cells):200 nM, MMP1:6.6 nM, MMP13:3 nM, ADAM10:16 nM(ki), ADAM17/TACE:8.4 nM (IC50) |
体外活性 |
TMI 1 inhibits LPS-induced TNF-α secretion in Raw and THP-1 cells (IC50s = 40 and 200 nM, respectively), as well as in isolated human monocytes and whole blood (IC50s = 190 and 300 nM, respectively).[1] It inhibits the production of TNF-α ex vivo in synovium isolated from the inflamed joints of patients with rheumatoid arthritis with IC50 values of less than 100 nM without inhibiting TNF-α expression in vitro.[3] |
体内活性 | TMI 1 inhibits LPS-induced TNF-α production in mice (ED50 = 5 mg/kg) and reduces disease severity in mouse models of collagen-induced arthritis. It also decreases cell viability of (ED50s = 1.3-8.1 μM), and induces caspase-3/7 activity in, a variety of cancer cell lines and induces tumor apoptosis and reduces tumor growth in an MMTV-ErbB2/neu mouse model of breast cancer when administered at a dose of 100 mg/kg.[3] |
别名 | WAY-171318 |
分子量 | 398.5 |
分子式 | C17H22N2O5S2 |
CAS No. | 287403-39-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 35.9 mg/mL (410.4 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5094 mL | 12.5471 mL | 25.0941 mL | 62.7353 mL |
5 mM | 0.5019 mL | 2.5094 mL | 5.0188 mL | 12.5471 mL | |
10 mM | 0.2509 mL | 1.2547 mL | 2.5094 mL | 6.2735 mL | |
20 mM | 0.1255 mL | 0.6274 mL | 1.2547 mL | 3.1368 mL | |
50 mM | 0.0502 mL | 0.2509 mL | 0.5019 mL | 1.2547 mL | |
100 mM | 0.0251 mL | 0.1255 mL | 0.2509 mL | 0.6274 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TMI-1 287403-39-8 Apoptosis Proteases/Proteasome MMP WAY171318 TMI1 WAY-171318 TMI 1 WAY 171318 Inhibitor inhibitor inhibit